Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Sotorasib, also known as AMG-510, is an orally bioavailable drug that falls under the category of selective KRAS G12C covalent inhibitors. By locking the KRAS G12C protein in an in···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：225
Sotorasib, a novel small molecule targeted therapeutic agent, presents a promising treatment avenue for patients harboring the KRAS G12C mutation. The KRAS gene plays a pivotal rol···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：298
Sotorasib, a targeted therapy medication for non-small cell lung cancer (NSCLC), is particularly effective for patients carrying the KRAS G12C mutation. By inhibiting the activity ···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：276
Sotorasib, an oral inhibitor targeting the KRAS G12C mutation, is predominantly utilized in the treatment of non-small cell lung cancer (NSCLC). Clinical trials have demonstrated t···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：225
Adlumiz exhibits a diverse array of applications within the realm of medicine, functioning as a pharmacological intervention for the management of cachexia. Pertinently, the questi···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：232
Sotorasib, a novel targeted medication designed specifically for patients with NSCLC carrying the KRAS p.G12C gene mutation, represents a promising therapeutic option for those ind···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：219
Fidaxomicin, a novel antibiotic medication, is specifically designed to combat difficile-associated diarrhea by targeting the resilient strains that have developed resistance to co···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：264
Fidaxomicin is primarily utilized for the treatment of Clostridium difficile associated diarrhea in adults and children aged 6 months and above.Fidaxomicin currently has only origi···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：245
Fidaxomicinis a macrolide antibiotic that plays a role in the treatment of Clostridium difficile associated diarrhea (CDAD) by inhibiting the bacterial RNA polymerase to combat ref···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：254
Fidaxomicin exerts its pharmacological effects primarily through the inhibition of bacterial RNA polymerase and is frequently prescribed for the treatment of diarrheal episodes att···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：257
DIFICID is a medication used to treat Clostridium difficile associated diarrhea, and its use in specific populations requires particular caution.Use in Specific Populations?For cer···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：218
Fidaxomicin is a prescription medication that should be administered under the guidance of a physician. Patients are advised to undergo regular examinations, observe any discomfort···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：190
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3672024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：602025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：792025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：742025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：902025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：932025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
